AU2002326742B2 - KGF polypeptide compositions - Google Patents

KGF polypeptide compositions Download PDF

Info

Publication number
AU2002326742B2
AU2002326742B2 AU2002326742A AU2002326742A AU2002326742B2 AU 2002326742 B2 AU2002326742 B2 AU 2002326742B2 AU 2002326742 A AU2002326742 A AU 2002326742A AU 2002326742 A AU2002326742 A AU 2002326742A AU 2002326742 B2 AU2002326742 B2 AU 2002326742B2
Authority
AU
Australia
Prior art keywords
kgf
amino acid
inclusive
acid residues
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2002326742A
Other languages
English (en)
Other versions
AU2002326742A1 (en
Inventor
Kenneth Crawford
Denis J. Gospodarowicz
W. Michael Kavanaugh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis Vaccines and Diagnostics Inc
Original Assignee
Novartis Vaccines and Diagnostics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23217561&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2002326742(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Vaccines and Diagnostics Inc filed Critical Novartis Vaccines and Diagnostics Inc
Publication of AU2002326742A1 publication Critical patent/AU2002326742A1/en
Application granted granted Critical
Publication of AU2002326742B2 publication Critical patent/AU2002326742B2/en
Priority to AU2007214362A priority Critical patent/AU2007214362B2/en
Assigned to NOVARTIS VACCINES AND DIAGNOSTICS, INC. reassignment NOVARTIS VACCINES AND DIAGNOSTICS, INC. Alteration of Name(s) in Register under S187 Assignors: CHIRON CORPORATION
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/50—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2002326742A 2001-08-21 2002-08-21 KGF polypeptide compositions Ceased AU2002326742B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2007214362A AU2007214362B2 (en) 2001-08-21 2007-08-31 KGF polypeptide compositions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31388101P 2001-08-21 2001-08-21
US60/313,881 2001-08-21
PCT/US2002/026929 WO2003016505A2 (en) 2001-08-21 2002-08-21 Kgf polypeptide compositions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2007214362A Division AU2007214362B2 (en) 2001-08-21 2007-08-31 KGF polypeptide compositions

Publications (2)

Publication Number Publication Date
AU2002326742A1 AU2002326742A1 (en) 2003-05-29
AU2002326742B2 true AU2002326742B2 (en) 2007-05-31

Family

ID=23217561

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002326742A Ceased AU2002326742B2 (en) 2001-08-21 2002-08-21 KGF polypeptide compositions

Country Status (8)

Country Link
US (2) US7265089B2 (cg-RX-API-DMAC7.html)
EP (1) EP1429799A4 (cg-RX-API-DMAC7.html)
JP (2) JP2005500390A (cg-RX-API-DMAC7.html)
AU (1) AU2002326742B2 (cg-RX-API-DMAC7.html)
CA (1) CA2457781A1 (cg-RX-API-DMAC7.html)
MX (1) MXPA04001526A (cg-RX-API-DMAC7.html)
PL (1) PL374269A1 (cg-RX-API-DMAC7.html)
WO (1) WO2003016505A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112012000865A2 (pt) * 2009-07-17 2019-09-24 T Tabor Aaron "composição e método para a modificação genética cosmética de células substancialmente intactas"
US20160250298A1 (en) 2013-11-01 2016-09-01 Spherium Biomed S.L. Inclusion bodies for transdermal delivery of therapeutic and cosmetic agents
TW201613622A (en) * 2014-10-14 2016-04-16 Bionet Corp Composition for skincare and pharmaceutical composition and preparation method thereof
CN109402130A (zh) * 2018-11-23 2019-03-01 成都中医药大学附属医院 一种重组人角质细胞生长因子-1及其制备方法和用途
KR20230127721A (ko) * 2022-02-25 2023-09-01 한국해양과학기술원 온도안정성을 향상시킨 fgf7 폴리펩타이드 및 그 용도

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011949A2 (en) * 1994-10-13 1996-04-25 Amgen Inc. Analogs of keratinocyte growth factor
WO1998024813A2 (en) * 1996-12-06 1998-06-11 Amgen Inc. Keratinocyte growth factors and their use in combination with glucagon-like peptide derivatives

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0555205T3 (da) 1989-01-31 2001-03-05 Jeffrey S Rubin DNA, der koder for en væstfaktor, som er specifik for epitelceller
US5194596A (en) 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
US5655870A (en) * 1993-03-01 1997-08-12 Kawasaki Steel Corporation Stacker crane in a warehouse
US5814605A (en) 1993-03-26 1998-09-29 Amgen Inc. Therapeutic uses of keratinocyte growth factor
NZ266622A (en) 1993-06-29 1997-10-24 Chiron Corp Keratinocyte growth factor fragment (kgf) with at least a 2-fold increase in mitogenic activity compared to a full length kgf; dna molecules, expression vectors, host cells, and conjugates
SI0785950T1 (en) 1994-10-13 2003-08-31 Amgen Inc. Keratinocyte growth factor analogs
DK0785949T3 (da) * 1994-10-13 2003-08-18 Amgen Inc Fremgangsmåde til oprensning af keratinocytvækstfaktorer
US5841605A (en) * 1996-11-06 1998-11-24 Iomega Corporation Caddy for cartridge and disk drive accomodating a caddy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996011949A2 (en) * 1994-10-13 1996-04-25 Amgen Inc. Analogs of keratinocyte growth factor
WO1998024813A2 (en) * 1996-12-06 1998-06-11 Amgen Inc. Keratinocyte growth factors and their use in combination with glucagon-like peptide derivatives

Also Published As

Publication number Publication date
CA2457781A1 (en) 2003-02-27
JP2009221207A (ja) 2009-10-01
JP2005500390A (ja) 2005-01-06
US7265089B2 (en) 2007-09-04
PL374269A1 (en) 2005-10-03
WO2003016505A2 (en) 2003-02-27
US20080200378A1 (en) 2008-08-21
EP1429799A4 (en) 2005-12-21
MXPA04001526A (es) 2004-05-31
US20030109439A1 (en) 2003-06-12
WO2003016505A3 (en) 2004-01-08
EP1429799A2 (en) 2004-06-23

Similar Documents

Publication Publication Date Title
EP1751184B1 (en) Fgf-21 fusion proteins
AU2005283025B2 (en) Muteins of fibroblast growth factor 21
AU646514B2 (en) Chimeric fibroblast growth factor
JP6181752B2 (ja) 線維芽細胞増殖因子21変異体
US20070265200A1 (en) Glycol Linked Fgf-21 Compounds
CA2232749C (en) Truncated glial cell line-derived neurotrophic factor
EP1831371A2 (en) Muteins of fibroblast growth factor 21
JP2004166709A (ja) 増加した生物学的活性を有する短縮型ケラチノサイト増殖因子(kgf)
US5736363A (en) IGF-II analogues
US20080200378A1 (en) KGF polypeptide compositions
SG185946A1 (en) Novel neurturin conjugates for pharmaceutical use
AU2002326742A1 (en) KGF polypeptide compositions
EP1961821B1 (en) Erythropoietin fusion protein
AU2007214362B2 (en) KGF polypeptide compositions
EP0668911A1 (en) Synthesis and purification of truncated and mutein forms of human ciliary neuronotrophic factor
CN1065875C (zh) 成纤维细胞生长因子-2结构类似物,其生产方法及应用
CA2079291A1 (en) Activities of heparin binding neurite-outgrowth promoting factor

Legal Events

Date Code Title Description
MK1 Application lapsed section 142(2)(a) - no request for examination in relevant period
NB Applications allowed - extensions of time section 223(2)

Free format text: THE TIME IN WHICH TO REQUEST EXAMINATION HAS BEEN EXTENDED TO 18 MAR 2006.

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired